BioCentury | Feb 19, 2021
Finance

Feb. 19 Quick Takes: New Horizon triples in Hong Kong IPO; plus Alta, Hangzhou Sciwind, Molecular Templates, BeiGene-BITT and Charles River-Cognate

...therapeutics and healthcare services companies. The San Francisco and Denver-based firm’s holdings include anti-infectives play Vir Biotechnology Inc....
BioCentury | Feb 19, 2021
Product Development

What works, what doesn’t and what’s next for COVID-19: Data Byte

...therapies, including six oral or subcutaneous therapies in the outpatient setting and an IV mAb from Vir Biotechnology Inc....
BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

...agreement to develop therapies for coronaviruses, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) gained exclusive rights to collaborate with Vir Biotechnology Inc. (NASDAQ:VIR) on...
...molecule immunoglobulin-associated betaFCGR2B (CD32B) –Fc gamma receptor IIbIL2RB (CD122) – Interleukin-2 receptor beta chain BC Staff GlaxoSmithKline plc Vir Biotechnology Inc. ImmuneID...
BioCentury | Feb 12, 2021
Product Development

How COVID-19 drug developers can stay ahead of viral variants

...one. FDA granted its casirivimab/imdevimab an EUA in November.Vir Biotechnology Inc....
BioCentury | Feb 10, 2021
Regulation

Lilly mAb combo gains EUA with shortened infusion time

...Lilly’s mAbs. Preclinical data so far suggest the mAbs are likely to lose efficacy.Lilly is collaborating with Vir Biotechnology Inc....
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...FactSet analysis named Ligand Pharmaceuticals Inc. (NASDAQ:LGND), Inovio Pharmaceuticals Inc. (NASDAQ:INO), Vaxart Inc. (NASDAQ:VXRT) and Vir Biotechnology Inc....
...is open until May 28. Paul Bonanos Sana Biotechnology Inc. CureVac N.V. Design Therapeutics Enthera s.r.l. Coalition for Epidemic Preparedness Innovations (CEPI) Vir Biotechnology Inc....
BioCentury | Jan 28, 2021
Finance

$1.9B fund gives Arch flexibility for more megarounds

...Inc. (NASDAQ:DNLI); CAR T play Juno Therapeutics Inc., acquired by Celgene Corp.; infectious disease company Vir Biotechnology Inc....
BioCentury | Jan 28, 2021
Product Development

Vulnerability of COVID-19 mAbs to emerging variants: Data Byte

...against emerging variants suggest that products from Vir Biotechnology Inc....
...LY-CoV016, JS016) VIR-7831 (GSK4182136) Regeneron Pharmaceuticals Inc. Eli Lilly and Co. Vir Biotechnology Inc. GlaxoSmithKline SARS-CoV-2...
BioCentury | Dec 19, 2020
Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

...development of medicines that could treat or prevent COVID-19. Two biotechs focused on infectious diseases, Vir Biotechnology Inc...
...to public health, it was very disappointing to recognize the new reality.” Steve Usdin Brii Biosciences Regeneron Pharmaceuticals Inc. Vir Biotechnology Inc. Eli...
BioCentury | Dec 19, 2020
Product Development

Why Vir, Brii believe their mAbs may succeed where others have failed

...arms will test VIR-7831, a mAb that Vir Biotechnology Inc....
...2021, the company said. Steve Usdin Brii Biosciences Regeneron Pharmaceuticals Inc. Vir Biotechnology Inc. Eli...
Items per page:
1 - 10 of 135
BioCentury | Feb 19, 2021
Finance

Feb. 19 Quick Takes: New Horizon triples in Hong Kong IPO; plus Alta, Hangzhou Sciwind, Molecular Templates, BeiGene-BITT and Charles River-Cognate

...therapeutics and healthcare services companies. The San Francisco and Denver-based firm’s holdings include anti-infectives play Vir Biotechnology Inc....
BioCentury | Feb 19, 2021
Product Development

What works, what doesn’t and what’s next for COVID-19: Data Byte

...therapies, including six oral or subcutaneous therapies in the outpatient setting and an IV mAb from Vir Biotechnology Inc....
BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

...agreement to develop therapies for coronaviruses, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) gained exclusive rights to collaborate with Vir Biotechnology Inc. (NASDAQ:VIR) on...
...molecule immunoglobulin-associated betaFCGR2B (CD32B) –Fc gamma receptor IIbIL2RB (CD122) – Interleukin-2 receptor beta chain BC Staff GlaxoSmithKline plc Vir Biotechnology Inc. ImmuneID...
BioCentury | Feb 12, 2021
Product Development

How COVID-19 drug developers can stay ahead of viral variants

...one. FDA granted its casirivimab/imdevimab an EUA in November.Vir Biotechnology Inc....
BioCentury | Feb 10, 2021
Regulation

Lilly mAb combo gains EUA with shortened infusion time

...Lilly’s mAbs. Preclinical data so far suggest the mAbs are likely to lose efficacy.Lilly is collaborating with Vir Biotechnology Inc....
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...FactSet analysis named Ligand Pharmaceuticals Inc. (NASDAQ:LGND), Inovio Pharmaceuticals Inc. (NASDAQ:INO), Vaxart Inc. (NASDAQ:VXRT) and Vir Biotechnology Inc....
...is open until May 28. Paul Bonanos Sana Biotechnology Inc. CureVac N.V. Design Therapeutics Enthera s.r.l. Coalition for Epidemic Preparedness Innovations (CEPI) Vir Biotechnology Inc....
BioCentury | Jan 28, 2021
Finance

$1.9B fund gives Arch flexibility for more megarounds

...Inc. (NASDAQ:DNLI); CAR T play Juno Therapeutics Inc., acquired by Celgene Corp.; infectious disease company Vir Biotechnology Inc....
BioCentury | Jan 28, 2021
Product Development

Vulnerability of COVID-19 mAbs to emerging variants: Data Byte

...against emerging variants suggest that products from Vir Biotechnology Inc....
...LY-CoV016, JS016) VIR-7831 (GSK4182136) Regeneron Pharmaceuticals Inc. Eli Lilly and Co. Vir Biotechnology Inc. GlaxoSmithKline SARS-CoV-2...
BioCentury | Dec 19, 2020
Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

...development of medicines that could treat or prevent COVID-19. Two biotechs focused on infectious diseases, Vir Biotechnology Inc...
...to public health, it was very disappointing to recognize the new reality.” Steve Usdin Brii Biosciences Regeneron Pharmaceuticals Inc. Vir Biotechnology Inc. Eli...
BioCentury | Dec 19, 2020
Product Development

Why Vir, Brii believe their mAbs may succeed where others have failed

...arms will test VIR-7831, a mAb that Vir Biotechnology Inc....
...2021, the company said. Steve Usdin Brii Biosciences Regeneron Pharmaceuticals Inc. Vir Biotechnology Inc. Eli...
Items per page:
1 - 10 of 135